Early Infant Diagnosis of HIV and Linkage to Antiretroviral Therapy in the Context of COVID-19 in Fifteen Sub-Saharan African Countries - Elizabeth Rabold, United States

International Workshop on HIV Pediatrics 2021

Impact of the COVID-19 Pandemic on Perinatal HIV Prevention in Canada: Canadian Perinatal HIV Surveillance Program - Joel Singer, Canada

International Workshop on HIV Pediatrics 2021

Bone Mineral Density/Content of Postpartum Mothers Taking Treatment Including DTG Vs EFV, TDF Vs TAF in Pregnancy and Their Infants: Randomized IMPAACT 2010 Trial - Tapiwa Mbengeranwa, Zimbabwe

International Workshop on HIV Pediatrics 2021

Hypertensive Disorders in Pregnancy and HIV: A Province-Wide Cohort Analysis During 2018 and 2019 in the Western Cape, South Africa - Amy Slogrove, South Africa

International Workshop on HIV Pediatrics 2021

Virological Failures and Genotypic Resistance in Children and Adolescents Randomised to Dolutegravir-Based ART vs. Standard-of- Care in the ODYSSEY Trial - Cissy Kityo, Uganda

International Workshop on HIV Pediatrics 2021

Longitudinal Study on Insulin Resistance and Metabolic Syndrome in Children with Perinatal HIV Infection and HIV Exposed Uninfected Children in South Africa - Claire Davies, South Africa

International Workshop on HIV Pediatrics 2021

Weight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY Trial - Hilda Angela Mujuru, Zimbabwe

International Workshop on HIV Pediatrics 2021

Pro (Children Should Be Prioritized) - Marieke van der Zalm, MD, MSc (Clin Epi), PhD

International Workshop on HIV Pediatrics 2021

LATE BREAKER - Dolutegravir-Based Art is Superior to Standard of Care in Young Children Living With HIV - Pauline Amuge, Uganda

International Workshop on HIV Pediatrics 2021

Clinical Impact and Cost-Effectiveness of Viral Load Testing (VLT) to Inform the Transition to Pediatric Dolutegravir (DTG) in Antiretroviral Therapy (ART)-Experienced Children With HIV in South Africa - Isaac Ravi Brenner, United States

International Workshop on HIV Pediatrics 2021

Pharmacokinetics and Safety of Dispersible- and Immediate-Release FDC Dolutegravir/Abacavir/Lamivudine in Children with HIV Weighing ≥14 Kg: Preliminary Results from IMPAACT 2019 - Kristina Brooks, United States

International Workshop on HIV Pediatrics 2021

B/F/Taf in Virologically Suppressed Adolescents and Children: Two- Year Outcomes in 6 to <18 Year Olds And Six-Month Outcomes in Toddlers - Eva Natukunda, Uganda

International Workshop on HIV Pediatrics 2021

Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the Smile PENTA-17 Trial - Alexandra Compagnucci, France

International Workshop on HIV Pediatrics 2021

Progress – and Lack of Progress - on DTG Transition in Children in Africa - Peter Elyanu, MBChB, M.Med, PhD

International Workshop on HIV Pediatrics 2021

Situation Report: African COVID-19 Pandemic in Children - Shabir Madhi, MBBCh, FCPaeds, PhD

International Workshop on HIV Pediatrics 2021

Approaches to Enhance and Accelerate Study of New Drugs for HIV and Coinfections in Pregnancy - Shahin Lockman, MD, MSc

International Workshop on HIV Pediatrics 2021

Long-Acting HIV Prevention in Adolescents: Possibilities and Challenges - Mina Hosseinipour, MD, MPH

International Workshop on HIV Pediatrics 2021

Pediatric HIV Treatment and Prevention: What’s New for 2021 - Martina Penazzato, MD, MSc, PhD

International Workshop on HIV Pediatrics 2021

The HIV Epidemic in Infants, Children, Adolescents and Women Today – 2021 UNAIDS Update - Mary Mahy, ScD, MHSc

International Workshop on HIV Pediatrics 2021